Profile data is unavailable for this security.
About the company
RTW Biotech Opportunities Ltd is a Guernsey-based focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. The Company invests in companies developing therapies and technologies that can significantly improve patients' lives. The Company seeks to achieve its investment objective by leveraging the Investment Manager's data driven pipeline of assets to invest in life sciences companies across various therapeutic categories and product types (including genetic medicines, biologics, traditional modalities, such as small molecule pharmaceuticals and antibodies, and medical devices). It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life. The Company's portfolio is managed by RTW Investments, LP.
- Revenue in USD (TTM)4.17m
- Net income in USD83.19m
- Incorporated2019
- Employees0.00
- LocationRTW Biotech Opportunities Ltd1st Floor, Royal Chambers,, St Julian's Avenue,PO Box 650SAINT PETER PORT GY1 3JXGuernseyGGY
- Phone+44 1 481742642
- Websitehttps://www.rtwfunds.com/rtw-biotech-opportunities-ltd/
Profile
| Management group(s) | RTW Investments, LP |
|---|---|
| AIC sector | Biotechnology & Healthcare |
| ISIN | GG00BKTRRM22 |
| Launch date | 29 Oct 2019 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | USD |
Objective
The Company seeks to achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life.
Managed by
| Naveen Yalamanchi, Roderick Wong, Stephanie Sirota, Sabera Loughran |
|---|
Management & contract fees
An annual management fee of 1.25% of the NAV. If the compounded NAV return exceeds 8% p.a., the manager will be entitled to a performance fee of 20%.
Mergers & acquisitions
| Acquired company | RTW:LSE since announced | Transaction value |
|---|---|---|
| Arix Bioscience PLC | 20.28% | 216.74m |
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Ashoka India Equity Investment Trust PLC | 88.58m | 69.24m |
| Admiral Acquisition Ltd | 0.00 | 13.74m |
| North American Income Trust PLC | -1.98m | -11.65m |
| Octopus Apollo VCT PLC | 58.64m | 36.30m |
| Mid Wynd International Invest Trust PLC | 53.52m | 49.04m |
| Octopus Renewables Infrastructr Trst PLC | 25.04m | 16.13m |
| JPmorgn Glbl Emrgng Mrkts Incm Trust PLC | -2.42m | -12.73m |
| Henderson European Focus Trust PLC | 101.25m | 95.63m |
| Third Point Investors Ltd | 38.67m | 11.42m |
| Dunedin Income Growth Investmnt Trst PLC | 35.47m | 29.00m |
| RTW Biotech Opportunities Ltd | 4.17m | 83.19m |
| JPmorgan Claverhouse Investment Trst PLC | 42.22m | 35.84m |
| Schroder Asian Totl Retrn Invstmt Co PLC | 55.26m | 44.93m |
| Abrdn Asia Focus PLC | 35.69m | 19.86m |
| Utilico Emerging Markets Trust PLC | 79.04m | 65.35m |
| Polar Capital Global Healthcare Trst PLC | 29.66m | 21.46m |
